1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
MedMira Inc.

MedMira Inc.

MIR.V
MedMira Inc.CA flagToronto Stock Exchange Ventures
0.06
CAD
- -
- -
38.60MMarket Cap
MedMira Inc.
MIR.V
(Toronto Stock Exchange Ventures)

Recent

price

0.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.01
- -
- -
0.01
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.02
-0.02
0.01
- -
-0.01
-0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
-0.01
- -
Basic EPS, GAAP
-0.01
-0.01
- -
- -
-0.01
- -
-0.01
- -
- -
- -
- -
- -
- -
- -
-0.01
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.37
-0.34
-0.05
-0.04
-0.03
-0.03
-0.03
-0.03
-0.04
-0.04
-0.04
-0.04
-0.04
-0.04
-0.05
-0.05
-0.06
Book Value per Share
-0.09
-0.09
-0.03
-0.02
-0.01
-0.01
-0.01
-0.01
-0.02
-0.02
-0.02
-0.02
-0.02
-0.02
-0.03
-0.03
-0.03
Tangible Book Value per Share
188
217
279
392
514
558
658
658
658
658
658
658
697
697
700
702
702
Basic Weighted Avg Shares
1
1
1
2
3
4
2
1
1
1
1
2
1
- -
- -
- -
- -
Sales/Revenue/Turnover
-217.79
-204.11
-243.62
-108.19
-141.15
-67.65
-198.46
-285.43
-312.51
-245.72
-141.46
0.27
-133.34
-411.1
-588.97
-1,433.98
-1,290.89
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-4
-5
3
- -
-4
-3
-5
-3
-3
-2
-2
-1
-2
-3
-3
-5
-3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-411.74
-541.75
347.43
-20.1
-151.7
-86.36
-228.57
-356.07
-426.15
-399.37
-222.55
-31.51
-192.37
-618.61
-806.25
-1,881.18
-1,853.95
Profit Margin (%)
-16
-19
-8
-4
-3
-5
-8
-9
-11
-14
-15
-16
-12
-14
-17
-20
-23
Working Capital
- -
- -
- -
5
4
2
- -
- -
- -
- -
3
2
2
3
3
4
2
LT Debt
-17
-19
-9
-9
-7
-8
-8
-9
-11
-14
-16
-16
-12
-15
-18
-23
-24
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
-22.8
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jul'25
Oct'26
Jan'26
ST Debt
6
7
7
LT Borrowings
2
- -
2
LT Finance Leases
2
2
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
702
702
702
Market Capitalization
56
56
46

Working Capital

FRC

•

in mil. unless spec.
Jul'25
Oct'26
Jan'26
Total Current Assets
2
2
2
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
1
1
1
Inventories
- -
- -
- -
Total Current Liabilities
22
25
25
Payables & Accruals
9
9
9
ST Debt
6
7
7
Deferred Revenue
1
1
1

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.36%
9.27%
25.08%
Free Cash Flow
37.03%
94.6%
-14.35%
Net Income, GAAP
18.48%
42.1%
36.02%
Sales/Revenue/Turnover
-9.17%
-4.63%
-41.7%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
-0.01
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Aeterna Zentaris Inc. (AEZS)
Amicogen, Inc. (092040.KQ)
Macrogen, Inc. (038290.KQ)
I-Mab (IMAB)
SYBLEU Inc (SYBE)
Shenzhen GuoHua Network Security Technology Co., Ltd. (000004.SZ)
Business
MedMira Inc. (TSX-V: MIR) develops, manufactures, and markets rapid point-of-care diagnostic tests for infectious diseases, including HIV, hepatitis C, and other viral infections. The company offers Reveal, Multiplo, and Sure Check product lines, which utilize proprietary rapid horizontal flow technology for lab-accurate results in minutes using fingerstick whole blood, serum, plasma, or oral fluid samples; these tests target professional and consumer markets with features like built-in controls, disposable cartridges, and compatibility with desktop analyzers. Operations span North America, Europe, Asia, and select emerging markets, with headquarters in Halifax, Nova Scotia, Canada, where the company was founded in 1994. Subsidiaries include MedMira Laboratories for R&D and manufacturing. In late 2024, MedMira launched expanded Multiplo multiplex tests for simultaneous detection of multiple infections and formed a strategic distribution alliance with a major Asian healthcare partner to accelerate market penetration in high-prevalence regions. Recent funding included a CAD 5 million equity raise in Q3 2025 to support U.S. FDA submissions for next-generation HIV self-tests and production scaling.